I was busy for a day and the market does great but I come back and we have a gap lower. Sorry. In all seriousness, however, the snap back rally needs to pause but given the sell-off, I think we need to see the market shake off the gap lower and end higher today. We […]
August 10 Biotech Update
We are getting a spurt of IO collaborations this morning but no major news or M&A. After the sell off Friday (and come back), I would not be surprised to see that positive momentum continue this morning. Worst case scenario would be early strength and then faded all day. Best case, obviously, would be early […]
July 31 Biotech Update
Not a lot of news so I want to round out a couple of issues this morning and close it out for the week. I am finding it more and more difficult to note whether the sector is strong or weak, which makes me think the best description is choppy. Overall it seems like modest […]
July 21 Biotech Update
The sector was green again yesterday and this morning but it does not seem to be a broad based move. The small caps appear to be underperforming and among the large caps it seems isolated to CELG with AMGN and GILD being relatively weak. This narrowing of the move tells me that we are much […]
July 7 Biotech Update
There is a little more news today but still relatively quiet. The market seems to be looking for a direction but the sector seems to be outperforming to the upside. Yesterday was certainly better than expected but it also did not end in an exceptionally bullish manner. That is why I still think the market […]
July 3 Biotech Update
This is the last note before the fourth and I wanted to spend time going into a new therapeutic space and highlight a new company (well, it is new to me but has already had a good run this year). I also wanted to wrap up the discussion from yesterday as the trading action is […]
April 22 Biotech Update
Another busy day so I have to keep this very short as I am trying to squeeze this in between meetings. In general, the sector seems to be doing fine and modestly outperforming the market. It remains to be seen if this is a sustainable move or whether it is a bounce from new M&A […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
March 3 Biotech Update
The market is weaker today and it is bringing down the sector, although it appears that biotechs are underperforming the broader market. It does not appear that this underperformance is concentrated in any market cap group or therapeutic area and simply looks like broadly hitting the sell button. Not exactly sure why the selling was […]
February 4 Biotech Update
So it looks like the sector wants to go lower. While there can be any number of explanations the proximate cause is the GILD report, so I want to go over that in detail and trace out what it means and does not mean. 1. Why is GILD down? I think this is the simplest […]
January 7 Biotech Update
A much better market today than the past couple of days. Over the near term I suspect the market is set up for a fairly significant bounce. Of course, the normal caveats all apply and we need to see follow through this afternoon but my base case is a nice recovery for the market which […]
December 30 Biotech Update
A drifting day in the market but with a negative bias to start. It is hard to read too much into the movement as the volume is low and there is little news out there. I am going to spend the next couple of notes previewing 2015 to a certain extent. I will start with […]
December 4 Biotech Update
A blah start to the trading day. There are not a particularly large numbers of movers and the market seems for the most part to be drifting. As such, it is difficult to discern any real trend outside of chop. So it seems like the market and sector are searching for a direction. I would […]
October 17 Biotech Update
Looks like we are clearly having the bounce that everyone has been expecting (expect during the height of the selling where everyone expected the market to go to zero). This should have fairly significant legs even if it is a dead cat bounce. At this point the conservative stance is to stay agnostic about the […]
October 2 Biotech Update
Surprise, surprise but the markets a not great (again). While we are not seeing the selling (yet), there is still not a lot of buying going on. We did get that additional move down I was expecting but I still have the sense that the path of least resistance is lower but we are probably […]
[Free Report] Tekmira Authorized to Treat Ebola; Amgen Seeks Approval for BiTE
Shares of Tekmira are up over 15% midday on news the FDA has authorized the company to provide the drug TKM-Ebola for treatment of subjects with confirmed or suspected Ebola virus infections under expanded access protocols. Tekmira has long been the subject of speculation over approval of its drug for the treatment of Ebola. The […]
August 4- Biotech Update
It was an interesting start to the week with Ebola and ASPIRE. It was strange that the sector was strong to start but seemed to hit a quick air pocket. Given how far the market has sold off, I would be very surprised not to see a bounce back this week but the market needs […]
April 30 Biotech Update
It is not Tuesday so the selling continues. It seems like the turnaround Tuesdays happen but have no sticking power. At some point that trend will change and that should be an important tell. Whether that happens today or in a couple of months is not clear at this time but as long as the […]
April 23 Biotech Update- Shooting Out of the Earnings Gate
This was a relatively slow news day (compared to yesterday and Monday) but there is still a lot to talk about with the large cap earnings. The sector did not responsd great but it is still early and I want to see how it closes before judging this reaction. In addition, the market backdrop was […]
March 31 Biotech Update- Is this the Bounce We are Looking For?
So this seems to be the rally we were looking for but that is assuming it does not fade in the afternoon like every other recent rally attempt. So far the rally is a little more broad based and stronger but we have seen this story before. That being said even if this is the […]
